Long-term growth of children with autoantibody-mediated congenital heart block.

Acta paediatrica (Oslo, Norway : 1992)

PubMedID: 23551183

Skog A, Eliasson H, Tingström J, Källberg H, Salomonsson S, Swedish Congenital Heart Block Study Group, Sonesson SE, Wahren-Herlenius M. Long-term growth of children with autoantibody-mediated congenital heart block. Acta Paediatr. 2013;102(7):718-26.
AIM
To analyse growth of children with and without congenital heart block (CHB) born to anti-Ro/SSA positive mothers from birth to 18 years of age, using a population-based cohort of Swedish CHB patients.

METHODS
Medical records for siblings with (n = 72) and without (n = 60) CHB born 1973-2009 to anti-Ro/SSA positive mothers were retrieved from child healthcare centres and school health services and used to extract data on growth from birth to 18 years.

RESULTS
Compared with reference standards, children with CHB were retarded in weight by 0.75-1.0 SD from birth to 2-3 years of age. Thereafter, the CHB children started to catch up, reaching the reference standards at 9-11 years of age. Pacemaker treatment was not correlated with the catch-up in growth. Individuals with CHB were retarded in both weight and height from birth to 9-11 years of age when compared to siblings without CHB, who did not demonstrate restriction in these measurements.

CONCLUSION
Presence of CHB is a more important predictor of growth restriction than maternal rheumatic disease and foetal anti-Ro/SSA exposure. The restriction persists for several years after birth, despite pacemaker treatment, which highlights the importance of follow-up of children with CHB regarding nutrition and growth.